Peregrine Submits Tarvacin Antiviral Investigational New Drug Application

Peregrine Pharmaceuticals has submitted an investigational new drug application (IND) to the FDA to initiate a Phase I clinical trial using Tarvacin to treat patients with chronic hepatitis C virus infection.

The objectives of the Phase I clinical protocol submitted in the IND are to evaluate safety, pharmacokinetics and viral load in patients chronically infected with hepatitis C virus who have failed standard treatment. There are estimated to be 2.7 million people in the U.S. and 170 million people worldwide with chronic hepatitis C infection.